



Currently Funded Gateway Research Studies

Blood/Hematologic Malignancies

1. Dr. Charalambos Andreadis, University of California, San Francisco
Use of anti-HGF antibody in treatment of refractory AML
Phase Ib Study of Anti-HGF Antibody with High Dose Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia. [G-14-100, State: CA]
2. Dr. David Avigan, Beth Israel Deaconess Medical Center
Powerful New Tools for Battling Myeloma
Blockade of PD-1 in conjunction of dendritic cell/myeloma vaccines following stem cell transplant [G-08-043, State: MA]
3. Dr. Alexandra Carey, Boston Children's Hospital
Intravenous Fish Oil Lipid Emulsion in Children Undergoing Cell Transplantation
The safety and tolerability of intravenous fish oil lipid emulsion in children undergoing hematopoietic cell transplantation [G-15-1200, State: MA]
4. Dr. Nelson Chao, Duke University
Microbiome and Stem Cell Transplantation: Home Care vs. Standard Hospital Care
A controlled study of stem cell transplantation medical home care compared to standard hospital care [G-13-300, State: NC]
5. Dr. Sung Choi, University of Michigan
Approved Drug that will Reduce Graft vs Host Disease in Bone Marrow Transplant Patients
Phase II Clinical Trial of Vorinostat plus Standard Immunosuppression after Unrelated Donor Myeloablative BMT [G-15-200, State: MI]
6. Dr. Christopher Cogle, University of Florida
Personalized Treatment of Patients with MDS
Personalized Genomic Mutation Informed Treatment of Patients with Myelodysplastic Syndromes (MDS) [G-15-700, State: FL]
7. Dr. Gary Deng, Memorial Sloan-Kettering Cancer Center
Acupuncture for Symptom Control in Stem Cell Transplantation Patients
Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients: a Pilot Study [G-13-500, State: NY]
8. Dr. Christoph Driessen, Kantonsspital St.Gallen (Switzerland)
Treating Chemo-Resistant Multiple Myeloma with HIV Drug
A Phase II single arm, multicenter clinical trial to assess the potential activity of oral nelfinavir combined with standards bortezomib in myeloma patients that have failed prior proteasome inhibitor-containing therapy [G-13-800, Switzerland]
9. Dr. Tanja Gruber, St. Jude Children' s Hospital
Therapy for Infants with ALL
Total Therapy for Infants with Acute Lymphoblastic Leukemia (ALL) [G-15-900, State: TN]



Currently Funded Gateway Research Studies

10. Dr. Siddhartha Mukherjee, Columbia University
Innovative Strategy for the Treatment of MDS
A Phase 1 Trial of Personalized/Precision Therapeutics for Myelodysplastic Syndrome (MDS) using Bone Marrow Organoid (BM-o) Screening [G-16-200, New York]
11. Dr. Adrian Ochsenbein, University Hospital Bern Inselspital (Switzerland)
Study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia
A Phase I/II study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia [G-15-1800, Switzerland]
12. Dr. David Schwartz, John Theurer Cancer Center at Hackensack University
Novel Study to Reduce Graft vs. Host Disease in Transplant Recipients
A Phase I/II Study of Telmisartan to Reduce Graft vs. Host Disease in Allogeneic Hematopoietic Cell Transplant Recipients, with Nested Biomarkers Studies [G-14-1100, State: NJ]
13. Dr. Radek Skoda, University of Basel (Switzerland)
Novel Treatment of Myeloproliferative Neoplasms
A Phase II Study to Test the Effects of Beta-3 Sympathomimetic Agonists on the Disease Course and Mutant Allele Burden in patients with Myeloproliferative Neoplasms [G-14-400, Switzerland]
14. Drs. Noel Raynal and Henrique Bittencourt, CHU Sainte-Justine (Canada)
Combination Therapy for Pediatric Patients with Solid Tumors and Leukemia
A Phase I/IIa Study of Decitabine in Combination with Genistein in Pediatric Patients with Relapsed or Refractory Solid Tumors and Leukemia [G-14-1200, Canada]
15. Dr. Alan Wayne, Children's Hospital Los Angeles
Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Consortium Study
A Pilot Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapse of Acute Lymphoblastic Leukemia – A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Consortium Study [G-15-500, State: CA]
16. Dr. Jane Winter, Northwestern University
A New Drug that Targets PD-1 and Restarts the Body's Ability to Attack Any Hiding Tumor Cells
Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission [G-15-100, State: IL]
17. Dr. Jeffery Wong, City of Hope
Targeted Radiation Therapy to Reduce Toxicity in Bone Marrow Transplantation
Evaluating the impact of functional/metabolic tumor imaging on image guided total marrow and lymphoid irradiation in acute leukemia patients undergoing hematopoietic cell transplantation (HCT) [G-13-400, State: CA]



Currently Funded Gateway Research Studies

Bone

18. Dr. Frank Balis, The Children's Hospital of Philadelphia

Prevention of Nephrotoxicity in Pediatric Osteosarcoma

Pilot Study to Prevent the Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent the Nephrotoxicity and Ototoxicity of Cisplatin with Pantoprazole in Children and Adolescents with Osteosarcoma [G-13-100, State: PA]

Brain

19. Dr. Robert Aiken, The State University of New Jersey

IGF-1R Inhibitor for Patients with Recurrent Malignant Astrocytoma

Phase I/II Trial of the IGF-1R Inhibitor. AXL1717 for Treatment of Patients with Recurrent Malignant Astrocytoma [G-15-2300, State: NJ]

20. Dr. Behnam Badie, City of Hope

Immunotherapy using IL 13Ra2 for the Treatment of Malignant Glioma

Phase I Cellular Immunotherapy Study Using Optimized IL 13Ra2-Specific T Cells for the Treatment of Malignant Glioma [G-14-600, State: CA]

21. Dr. Pierre-Yves Dietrich, University Hospital Geneva (Switzerland)

Peptide Cancer Vaccine for Glioblastoma

Phase I/II study of peptide-based vaccine adjuvanted with poly-ICLC (Hiltonol) in combination with temozolomide as a maintenance treatment in newly diagnosed HLA-A2+ glioblastoma patients following treatment with radiation therapy and concurrent temozolomid [G-12-600, Switzerland]

22. Dr. Sarah Leary, Seattle's Children Hospital

New Treatment using Tumor Paint in Pediatric Patients with Brain Cancer

A Phase I and Expanded Imaging Study of BLZ-100 in Pediatric Patients with Primary Brain Tumors [G-14-900, State: WA]

23. Dr. Nathan Robison, Children's Hospital Los Angeles

A Phase I-II Trial Utilizing the Experimental Drug MEK162 for Brain Tumors in Children

A Phase I-II Trial of MEK162 for Progressive/Recurrent Low Grade Gliomas and Other Ras/Raf/MEK/ERK-Pathway-Activated Tumors in Children [G-16-400, State: CA]

24. Dr. Katy Rezvani, MD Anderson Cancer Center

Cytomegalovirus as a Novel Treatment for Immunotherapy of Glioblastoma Multiforme

Targeting Cytomegalovirus as a Novel Treatment for Immunotherapy of Glioblastoma Multiforme [G-16-500, State: TX]



Currently Funded Gateway Research Studies

Breast

25. Dr. Rebecca Aft, Washington University (St. Louis)

Effects of Herceptin on Survival in Breast Cancer Patients

A phase II randomized trial evaluating the effect of trastuzumab on disease free survival in early stage HER2-negative breast cancer patients with ERBB2 expressing bone marrow disseminated tumor cells [G-12-700, State: MO]

26. Dr. Kay Garcia, MD Anderson Cancer Center

The use of acupuncture in post-mastectomy Pain

Randomized-controlled trial of acupuncture for post-mastectomy pain syndrome [G-15-1400, State: TX]

27. Dr. Janet Horton, Duke University

Individualized Approach to Radiation Therapy for Breast Cancer

Preoperative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy [G-15-400, State: NC]

28. Dr. Nagi Kumar, Moffitt Cancer Institute

Ameliorating Symptoms of Cognitive Impairment in Women Treated with Chemotherapy for Breast Cancer

A Phase II clinical trial to ameliorate symptoms of cognitive impairment in women treated with chemotherapy for breast cancer: The COGNUTRIN Trial [G-13-200, State: FL]

29. Dr. Charles Loprinzi, Mayo Clinic

Evaluation of Scrambler Therapy for Chemotherapy- Induced Neuropathy

Phase II Evaluation of Scrambler Therapy for Treating Established Chemotherapy-Induced Neuropathy [G-15-1000, State: MN]

30. Dr. Christoph Mamot, Cantonal Hospital Aarau (Switzerland)

Potential New Pathway for Safe and Effective Targeted Delivery of Anticancer Drugs in Patients with Triple Negative Breast Cancer

Phase II study of ant-EGFR-ILs in patients with advanced triple negative breast cancer [G-14-500, Switzerland]

31. Dr. Olivia Pagani, International Breast Cancer Study Group (Switzerland)

Interruption of endocrine therapy for young breast cancer patients who desire pregnancy

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy [G-15-1900, Switzerland]

32. Dr. Mark Pegram, Stanford University

Novel Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy

Pilot phase I/II investigational study to assess the efficacy and safety of recombinant hyaluronidase (rHUPH20) in the treatment of secondary lymphedema resulting from local management of malignancy [G-13-700, State: CA]



Currently Funded Gateway Research Studies

33. Dr. Raquel Reinbolt, Ohio State University
Prevention of toxicity with Omega-3 Supplementation
Prevention of aromatase inhibitor-induced toxicity with Omega-3 supplementation
[G-15-1100, State: OH]

Colon / Colorectal

34. Dr. Edward Lin, Fred Hutchinson Cancer Research Center
Two-Step ADAPT Therapy for Metastatic Colorectal Cancer
A multi-center randomized phase II trial of ADAPT therapy vs standard of care for patients with metastatic colorectal cancer [G-11-103-1, State: WA]

35. Dr. Jordi Rodon, Vall d'Hebron Institute of Oncology (Spain)
A trial of Ivermectin as an anticancer
IVINCA trial (Ivermectin IN Cancer), a trial of Ivermectin as an anticancer WNT--TCF response inhibitor [G-15-2000, Spain]

36. Dr. Rina Rosin-Arbesfeld, Tel Aviv University (Israel)
Novel Use of Antibiotics to Treat Colorectal Cancer
Antibiotics as a Cure for Colorectal Cancer [G-13-600, Israel]

Head and Neck

37. Dr. Nicolas Mach, Geneva University Hospital (Switzerland)
Phase II Trial with personalized, cell based antitumor immunization
Personalized, cell-based antitumor immunization with MVX-ONCO-1, a combination of subcutaneous irradiated autologous tumor cells and encapsulated allogeneic cells engineered to release GM-CSF: a single arm Phase II trial [G-15-1700, Switzerland]

Lung

38. Dr. Khanh Do, Dana-Farber Cancer Institute
Patients with Advanced Solid Tumors
Phase 1 Study of the Hsp90 inhibitor, AT13387, and the CDK inhibitor, AT7519, in Patients with Advanced Solid Tumors [G-15-1300, State: MA]

39. Dr. Shirish Gadgeel, Karmanos Cancer Institute
Combination of Anti-PD-1 and EGFR-BATs for Lung Cancer Patients
Phase I/II Trial Evaluating The Combination Of Anti-PD-1 Pembrolizumab And EGFR-BATs as Maintenance Therapy For Advanced Non-Small Cell Lung Cancer Patients [G-15-800, State: MI]

40. Dr. Richard Pietras, UCLA Jonsson Comprehensive Cancer Center
Combination Therapy for Advanced Non-Small Cell Lung Cancer
Clinical investigation of combination treatment with an aromatase inhibitor (exemestane) and carboplatin-based therapy for postmenopausal women with advanced NSCLC
[G-11-101-1, State: CA]



Currently Funded Gateway Research Studies

41. Dr. Sacha Rothschild, University Hospital (Switzerland)
Neoadjuvant chemotherapy in non-small cell lung cancer patients
Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in non-small cell lung cancer (NSCLC) patients with mediastinal lymph node metastases [G-15-2100, Switzerland]

42. Dr. Dugald Seely, Canadian College of Naturopathic Medicine
Melatonin's Clinical Effects on Immune and Inflammatory Systems
Adjuvant melatonin in prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo control trial [G-12-100, Canada]

Ovarian

43. Dr. Anil Sood, MD Anderson Cancer Center
Overcoming Adaptive Changes following Deprivation of Blood Supply to Tumors in Ovarian Cancer
Targeting Adaptive Changes Following Anti-angiogenesis Therapy in Ovarian cancer [G-16-100, State: TX]

Pancreatic

44. Dr. Nilofer Azad, John Hopkins University
Epigenetic Therapy in Resected Pancreatic Cancer
A randomized phase II trial of epigenetic therapy in high-risk resected pancreatic cancer patients [G-15-600, State: MD]

45. Dr. David A Boothman, University of Texas Southwestern Medical Center
Exploiting NQO1 Enzyme in a Tumor-Selective Manner for Pancreatic Cancer Therapy
Exploiting an NQO1 "kiss of death" for pancreatic cancer therapy [G-14-300, State: TX]

46. Dr. Joseph Cullen, University of Iowa College of Medicine
Treating Pancreatic Cancer with Gemcitabine, Ascorbate and Radiation
Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I [G-14-800, State: IA]

47. Dr. Bryan Hennessy, Royal College of Surgeons (Ireland)
Nab-Paclitaxel therapy in advanced pancreatic cancer
Phase II, open label clinical trial of inecalcitol in combination with in combination with gemcitabine/Nab-Paclitaxel therapy in advanced pancreatic cancer [G-15-2200, Ireland]

48. Dr. Lei Zheng, Johns Hopkins University
Phase II Study for the Treatment of Patients with Advanced Adenocarcinoma of the Pancreas
A Phase II Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination with a PD-1 Blockade Antibody (Pembrolizumab) for the Treatment of Patients with Locally Advanced Adenocarcinoma of the Pancreas [G-16-600, State: MD]



Currently Funded Gateway Research Studies

Prostate

49. Dr. Sanjay Gupta, Case Western Reserve University

Polyphenols in Prostate Cancer

Use of polyphenon E in men with low-risk prostate cancer on active surveillance

[G-12-200, State: OH]

50. Dr. Dana Rathkopf, Memorial Sloan Kettering Cancer Center

Men with Castration-Resistant Prostate Cancer

A Phase 1b/2 Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate

Cancer (CRPC) [G-15-1500, State: NY]

51. Dr. Ulka Vaishampayan, Karmanos Cancer Institute

Metastatic Castrate Resistant Prostate Cancer

Phase II Trial evaluating efficacy of bispecific antibody armed T cells (BATs) in metastatic

castrate resistant prostate cancer (mCRPC) [G-15-1600, State: MI]

Renal

52. Dr. Toni Choueiri, Dana Farber Cancer Institute

A Personalized Neoantigen Vaccine with Ipilimumab to Treat Clear Cell Renal Carcinoma

Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced

Clear Cell Renal Carcinoma [G-14-1000, State: MA]

Sarcoma

53. Dr. Nancy Gordon, MD Anderson Cancer Center

Phase I Chemotherapy Spray for Patients with Solid Tumors and Lung Metastases

Phase I Aerosol Gemcitabine for Patients with Solid Tumors and Lung Metastases

[G-16-300, State: TX]

Skin

54. Dr. Holbrook Kohrt, Stanford Cancer Institute

In-Human Clinical Trial of a Novel Immunotherapeutic Paradigm for Cancer Treatment

A Phase I/II Trial of Intratumoral Ipilimumab and Radiotherapy – Treat Local, Cure Global

[G-14-200, State: CA]

55. Dr. Patricia LoRusso, Yale Cancer Center

Personalized Medicine for Patients with BRAF Wild-Type Cancer

Personalized Medicine for Patients with BRAF Wild-Type Cancer, Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients with BRAF wild-type

(BRAFWt) Metastatic Melanoma [G-15-300, State: CT]